Göhring U J, Scharl A, Thelen U, Ahr A, Crombach G
Department of Obstetrics, University of Cologne, Germany.
Anticancer Res. 1996 Mar-Apr;16(2):1011-8.
The lysosomal protease Cathepsin D and the serine protease urokinase plasminogen activator (uPA) are suspected to indicate poor prognosis in primary breast carcinoma. We tested Cathepsin D and uPA immunohistochemically in 281 surgical specimens of primary ductal infiltrating breast carcinomas. Staining was evaluated, taking intracytoplasmic immunoreactions into account, in tumour cells and tumour infiltrating macrophages. Positivity was established in 48.4% and 58.0% of tissue samples for cathepsin D and uPA respectively (co-expression: 67.6%). In patients with cathepsin D- or uPA-positive tumours, relapses were more frequent and disease-free survival was shorter irrespective of nodal status, receptor status or menopausal status, (median observation time 74 months). However, this trend was statistically significant only for cathepsin D. With stepwise cox regression analysis, borderline significance (p = 0.07) was calculated for cathepsin D only in node-negative patients. The combination of cathepsin D with uPA measurements did not enhance its prognostic value. Immunohistochemical detection of Cathepsin D could potentially be used to identify patients with poor prognosis in the group of node negative breast cancer patients.
溶酶体蛋白酶组织蛋白酶D和丝氨酸蛋白酶尿激酶型纤溶酶原激活剂(uPA)被怀疑提示原发性乳腺癌预后不良。我们对281例原发性浸润性导管乳腺癌手术标本进行了组织蛋白酶D和uPA的免疫组化检测。评估染色情况时,将肿瘤细胞和肿瘤浸润巨噬细胞的胞浆内免疫反应考虑在内。组织蛋白酶D和uPA在组织样本中的阳性率分别为48.4%和58.0%(共表达率:67.6%)。在组织蛋白酶D或uPA阳性肿瘤患者中,无论淋巴结状态、受体状态或绝经状态如何,复发都更频繁,无病生存期更短(中位观察时间74个月)。然而,这种趋势仅在组织蛋白酶D方面具有统计学意义。通过逐步Cox回归分析,仅在淋巴结阴性患者中组织蛋白酶D的p值为临界显著(p = 0.07)。组织蛋白酶D与uPA检测相结合并未提高其预后价值。组织蛋白酶D的免疫组化检测可能可用于识别淋巴结阴性乳腺癌患者中预后不良的患者。